Portal hypertension activates the nitric oxide synthase genes in the esophageal mucosa of rats

1996 ◽  
Vol 110 (2) ◽  
pp. 549-557 ◽  
Author(s):  
K Tanoue ◽  
M Ohta ◽  
AS Tarnawski ◽  
KJ Wahlstrom ◽  
K Sugimachi ◽  
...  
2004 ◽  
Vol 286 (2) ◽  
pp. G294-G303 ◽  
Author(s):  
Bao Luo ◽  
Lichuan Liu ◽  
Liping Tang ◽  
Junlan Zhang ◽  
Yiqun Ling ◽  
...  

Common bile duct ligation (CBDL) triggers a molecular cascade resulting in the hepatopulmonary syndrome (HPS). Both increased hepatic endothelin-1 (ET-1) production and pulmonary vascular ETB receptor expression with stimulation of endothelial nitric oxide synthase and TNF-α mediated inducible nitric oxide synthase and heme oxygenase-1 expression in pulmonary intravascular macrophages occur. Whether biliary cirrhosis is unique in triggering ET-1 and TNF-α alterations and HPS is unknown. We evaluated for HPS in rat prehepatic portal hypertension [partial portal vein ligation (PVL)], biliary (CBDL) and nonbiliary [thioacetamide treatment (TAA)] cirrhosis, and assessed ET-1 infusion in normal and PVL animals. Control, PVL, CBDL, TAA-treated, and ET-1-infused PVL animals had ET-1 and TNF-α levels measured and underwent molecular and physiological evaluation for HPS. HPS developed only in biliary cirrhosis in association with increased plasma ET-1 and TNF-α levels and the development of established molecular changes in the pulmonary microvasculature. In contrast, PVL did not increase ET-1 or TNF-α levels and TAA treatment increased TNF-α levels alone, and neither resulted in the full development of molecular or physiological changes of HPS despite portal pressure increases similar to those after CBDL. Exogenous ET-1 increased TNF-α levels and triggered HPS after PVL. Combination of ET-1 and TNF-α overproduction is unique to biliary cirrhosis and associated with experimental HPS. ET-1 infusion increases TNF-α levels and triggers HPS in prehepatic portal hypertension. ET-1 and TNF-α interact to trigger pulmonary microvascular changes in experimental HPS.


2000 ◽  
Vol 119 (1) ◽  
pp. 196-200 ◽  
Author(s):  
Dominique Pateron ◽  
Khalid A. Tazi ◽  
Philippe Sogni ◽  
Jörg Heller ◽  
Carine Chagneau ◽  
...  

2003 ◽  
Vol 124 (5) ◽  
pp. 1500-1508 ◽  
Author(s):  
Nicholas G Theodorakis ◽  
Yi-ning Wang ◽  
Nicholas J Skill ◽  
Matthew A Metz ◽  
Paul A Cahill ◽  
...  

1999 ◽  
Vol 277 (2) ◽  
pp. G463-G468 ◽  
Author(s):  
Vijay Shah ◽  
Reiner Wiest ◽  
Guillermo Garcia-Cardena ◽  
Greg Cadelina ◽  
Roberto J. Groszmann ◽  
...  

The molecular chaperone, heat shock protein 90 (Hsp90), acts as an intermediate in the signaling cascades leading to activation of endothelial nitric oxide synthase (eNOS). In this study, we examine the participation of this pathway in nitric oxide (NO)-dependent vasodilation in the rat mesentery in vitro. In normal animals, immunoprecipitation of eNOS from intact mesentery coimmunoprecipitates Hsp90 and, additionally, both eNOS and Hsp90 colocalize to the endothelial lining of mesenteric vessels. In the perfused mesenteric vasculature of normal animals, geldanamycin (GA), a specific inhibitor of Hsp90 signaling, attenuates ACh-dependent vasodilation but does not affect vasodilation in response to sodium nitroprusside. Next, studies were performed in animals with experimental portal hypertension induced by portal vein ligation (PVL). In PVL animals, NOS catalytic activity is markedly enhanced in mesenteric tissue and the perfused mesentery is hyporesponsive to the vasoconstrictor methoxamine (MTX). GA significantly potentiates MTX-induced vasoconstriction after PVL, thereby partially reversing the hyporeactivity to this agent exhibited in the mesenteric vasculature after PVL. These studies suggest that Hsp90 can act as a signaling mediator of NO-dependent responses in the mesenteric circulation and indicate that the excessive NO production observed in portal hypertension is mediated in part through Hsp90 signaling.


Sign in / Sign up

Export Citation Format

Share Document